Although the NSCLC patients with an ECOG PS of 0–1 depicted a better prognosis after a PD-1 blockade than those with an ECOG PS of 2–4, those with a PS of 2 exhibited a comparable prognosis to those with an ECOG PS of 0–1 in first-line pembrolizumab treatment for the population with a PD-L1 ≥ 50%. This evidence concerns the gene CD274 and non-small cell lung carcinoma.